Vanguard lists 2.28M shares of United Therapeutics (NASDAQ: UTHR)
Rhea-AI Filing Summary
Vanguard Capital Management reported beneficial ownership of 2,278,348 shares of United Therapeutics Corporation Common Stock, representing 5.19% of the class as of 03/31/2026. The filing shows Vanguard has sole voting power over 320,809 shares and sole dispositive power over 2,278,348 shares. The filing states these holdings include securities managed across Vanguard affiliates and funds.
Positive
- None.
Negative
- None.
Insights
Large passive stake reported by Vanguard; routine disclosure under Schedule 13G.
The filing lists 2,278,348 shares and a 5.19% stake as of 03/31/2026. This indicates institutional aggregation across Vanguard business divisions and funds rather than an activist intent, consistent with passive investor reporting.
Watch subsequent filings for changes in percentage or voting power; material shifts would appear in amended Schedule 13G/13D filings.
Voting and dispositive splits clarify how Vanguard exercises influence.
The report shows sole voting power for 320,809 shares and sole dispositive power for 2,278,348 shares. That gap signals most holdings are managed for clients with dispositive authority concentrated in the reporting entity.
If voting activism were intended, expect increased sole voting counts or a Schedule 13D amendment; none is shown here.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficially owned financial
Dispositive power regulatory
Investment Company Act regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.